Analysis of Genetic Risk Factors Associated with Charcot Foot Based on the FinnGen Study R9 Data: A Wide-angle Mendelian Randomization Study

Abstract

Background

Charcot foot or Charcot neuropathic joint disease (CN) is a rare and complex foot disease with unknown pathogenesis, hindering early identification and intervention. The study aimed to clarify the causal association between all predominant risk factors and CN.

Methods

Two-sample Mendelian Randomization (MR), Multivariate MR, and Bidirectional MR analyses investigated the causal association between 36 modifiable risk factors and CN. The causal relationship between CN and Inflammatory cytokine and immune cells was also analyzed.

Results

Genetic factors associated with obesity and genetic susceptibility to various autoimmune diseases and non-cancerous thyroid diseases increased the risk of CN (P < .05), genetically associated high basal metabolic rate and high total cholesterol decreased the risk of CN (P < .05). In addition, we found a bi-directional causal relationship between CN and diabetes. In further immune cell analysis, we found 8 CN related immune cells, and in inflammatory cytokine analysis, we found 2 CN related inflammatory cytokines.

Conclusions

This comprehensive MR Study supports the causal role of Obesity-related factors, diabetes, autoimmune-related factors, and smoking in the development and progression of CN. This study identifies a potential cause of CN that has not been identified in previous studies and provides a new direction for further research.

Keywords

Charcot foot Charcot neuropathic arthropathy (CN)Mendelian randomization cytokines immune cells

Get full access to this article

View all access options for this article.

References

Trepman

Nihal

Pinzur

. Current topics review: Charcot neuroarthropathy of the foot and ankle. Foot Ankle Int. 2005;26(1):46‐63. doi:https://doi.org/10.1177/107110070502600109.

Liu

Yang

Dong

. Diagnosis and treatment of Charcot’s osteoarthropathy. Zhongguo Gu Shang. 2019;32(12):1168‐1172. doi:https://doi.org/10.3969/j.issn.1003-0034.2019.12.021.

Papanas

Maltezos

. Etiology, pathophysiology and classifications of the diabetic Charcot foot. Diabet Foot Ankle. 2013;4. doi:https://doi.org/10.3402/dfa.v4i0.20872.

Sinacore

Bohnert

Smith

, et al. Persistent inflammation with pedal osteolysis 1year after Charcot neuropathic osteoarthropathy. J Diabetes Complications. 2017;31(6):1014‐1020. doi:https://doi.org/10.1016/j.jdiacomp.2017.02.005.

Korzon-Burakowska

Jakóbkiewicz-Banecka

Fiedosiuk

, et al. Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathy. Diabet Med. 2012;29(6):771‐775. doi:https://doi.org/10.1111/j.1464-5491.2011.03442.x.

Connors

Hardy

Kishman

, et al. Charcot pathogenesis: A study of in vivo gene expression. J Foot Ankle Surg. 2018;57(6):1067‐1072. doi:https://doi.org/10.1053/j.jfas.2018.03.023.

Kurki

Karjalainen

Palta

, et al. Finngen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508‐518. doi:https://doi.org/10.1038/s41586-022-05473-8.

Mbatchou

Barnard

Backman

, et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat Genet. 2021;53(7):1097‐1103. doi:https://doi.org/10.1038/s41588-021-00870-7.

Loh

Kichaev

Gazal

Schoech

Price

. Mixed-model association for biobank-scale datasets. Nat Genet. 2018;50(7):906‐908. doi:https://doi.org/10.1038/s41588-018-0144-6.

10.

Sakaue

Kanai

Tanigawa

, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021;53(10):1415‐1424. doi:https://doi.org/10.1038/s41588-021-00931-x.

11.

Dönertaş

Fabian

Valenzuela

Partridge

Thornton

. Common genetic associations between age-related diseases. Nat Aging. 2021;1(4):400‐412. doi:https://doi.org/10.1038/s43587-021-00051-5.

12.

Chiou

Geusz

Okino

, et al. Interpreting type 1 diabetes risk with genetics and single-cell epigenomics. Nature. 2021;594(7863):398‐402. doi:https://doi.org/10.1038/s41586-021-03552-w.

13.

Klimentidis

Raichlen

Bea

, et al. Genome-wide association study of habitual physical activity in over 377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE. Int J Obes (Lond). 2018;42(6):1161‐1176. doi:https://doi.org/10.1038/s41366-018-0120-3.

14.

Dashti

Daghlas

Lane

, et al. Genetic determinants of daytime napping and effects on cardiometabolic health. Nat Commun. 2021;12(1):900. doi:https://doi.org/10.1038/s41467-020-20585-3.

15.

Liu

Jiang

Wedow

, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet. 2019;51(2):237‐244. doi:https://doi.org/10.1038/s41588-018-0307-5.

16.

Chen

Spracklen

Marenne

, et al. The trans-ancestral genomic architecture of glycemic traits. Nat Genet. 2021;53(6):840‐860. doi:https://doi.org/10.1038/s41588-021-00852-9.

17.

Chen

Raffield

Mousas

, et al. Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. Cell. 2020;182(5):1198‐1213. e14. doi:10.1016/j.cell.2020.06.045.

18.

Vuckovic

Bao

Akbari

, et al. The polygenic and monogenic basis of blood traits and diseases. Cell. 2020;182(5):1214‐1231. e11. doi:https://doi.org/10.1016/j.cell.2020.08.008.

19.

Barton

Sherman

Mukamel

Loh

. Whole-exome imputation within UK Biobank powers rare coding variant association and fine-mapping analyses. Nat Genet. 2021;53(8):1260‐1269. doi:https://doi.org/10.1038/s41588-021-00892-1.

20.

Richardson

Leyden

Wang

, et al. Characterising metabolomic signatures of lipid-modifying therapies through drug target Mendelian randomisation. PLoS Biol. 2022;20(2):e3001547. doi:https://doi.org/10.1371/journal.pbio.3001547.

21.

Zhao

Stacey

Eriksson

, et al. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol. 2023;24(9):1540‐1551. doi:https://doi.org/10.1038/s41590-023-01588-w.

22.

Stuck

Sohn

Budiman-Mak

Lee

Weiss

. Charcot arthropathy risk elevation in the obese diabetic population. Am J Med. 2008;121(11):1008‐1014. doi:https://doi.org/10.1016/j.amjmed.2008.06.038.

23.

Nehring

Mrozikiewicz-Rakowska

Maroszek

, et al. Risk factors of charcot neuroarthropathy development in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2014;122(1):31‐34. doi:https://doi.org/10.1055/s-0033-1358483.

24.

Rabe

Winther-Jensen

Allin

Svendsen

. Fractures and osteoporosis in patients with diabetes with charcot foot. Diabetes Care. 2021;44(9):2033‐2038. doi:https://doi.org/10.2337/dc21-0369.

25.

Schmidt

. Clinical insights into Charcot foot. Best Pract Res Clin Rheumatol. 2020;34(3):101563. doi:https://doi.org/10.1016/j.berh.2020.101563.

26.

Carro

Saurral

Witman

, et al. Diabetic foot attack. Pathophysiological description, clinical presentation, treatment and outcomes. Medicina (B Aires). 2020;80(5):523‐530. Ataque de pie diabético. Descripción fisiopatológica, presentación clínica, tratamiento y evolución.

27.

Pixley

Stanley

. Chapter 319 – cytokines and cytokine receptors regulating cell survival, proliferation, and differentiation in hematopoiesis. In: Bradshaw

Dennis

, eds. Handbook of cell signaling, 2nd ed. Academic Press; 2010:2733‐2742.

28.

Gotlib

Horny

H-P

Valent

. Chapter 72 – mast cells and mastocytosis. In: Hoffman

Benz

Silberstein

, et al., eds. Hematology, 7th ed. Elsevier; 2018:1170‐1186.

29.

Kokaia

. NEUROTROPHIC FACTORS | GDNF: a neurotrophic factor against epilepsy. In: Schwartzkroin

, ed. Encyclopedia of basic epilepsy research. Academic Press; 2009:922‐925.

30.

Fauzi

Chung

Latif

. Risk factors of diabetic foot Charcot arthropathy: A case-control study at a Malaysian tertiary care centre. Singapore Med J. 2016;57(4):198‐203. doi:https://doi.org/10.11622/smedj.2016074.

31.

Deng

Luo

Chang

Ding

Xiao

. The emerging epigenetic role of CD8+T cells in autoimmune diseases: A systematic review. Front Immunol. 2019;10:856. doi:https://doi.org/10.3389/fimmu.2019.00856.

32.

Berg

Forman

. The role of CD8T cells in innate immunity and in antigen non-specific protection. Curr Opin Immunol. 2006;18(3):338‐343. doi:https://doi.org/10.1016/j.coi.2006.03.010.

33.

Klajman

Drucker

Mekori

. The importance of HLA-DR in autoimmune diseases. Isr J Med Sci. 1990;26(12):691‐692.

34.

Jin

Zheng

, et al. Checkpoint TIPE2 limits the helper functions of NK cells in supporting antitumor CD8(+) T cells. Adv Sci (Weinh). 2023;10(12):e2207499. doi:https://doi.org/10.1002/advs.202207499.

35.

Mitchell

Chintala

Dey

. Plasmacytoid dendritic cell in immunity and cancer. J Neuroimmunol. 2018;322:63‐73. doi:https://doi.org/10.1016/j.jneuroim.2018.06.012.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB